Despite their controversial physiology, sigma-1 (1) receptors are intriguing targets for the development of therapeutic agents for central nervous system diseases. With the aim of providing versatile pharmacological tools to study 1 receptors, we developed three 1 fluorescent tracers by functionalizing three well characterized 1 ligands with a fluorescent tag. A good compromise between 1 binding affinity and fluorescent properties was reached, and the 1 specific targeting of the novel tracers was demonstrated by different techniques: photolabeling, confocal microscopy and flow cytometry. These novel ligands were also successfully used in competition binding studies by flow cytometry, showing their utility in nonradioactive binding assays as an alternative strategy to the more classical radioligand binding assays. To the best of our knowledge these novel tracers are the first 1 fluorescent ligands to be developed, and represent promising tools to strengthen 1
Introduction
The existence of sigma (σ) receptors was first reported in 1976 when they were considered as subtypes of opiate receptors [1] . Later studies clarified that they are a unique set of proteins divided into two subtypes, namely 1 and 2. The 2 subtype is the lesser known: it has not yet been cloned, and different hypotheses about its identity have been formulated [3] [4] . Despite this paucity of information, interest in 2 receptor research is on the increase because this subtype is overexpressed in several cancers and its activation through ligands leads cancers cells to death [5] [6] [7] [8] . Worthy of note is also the efficacy of 2 ligands in resistant tumors that shed light on novel strategies for tumor treatments [9] . On the other hand, 1 receptor was cloned right after the two subtypes were discovered [10, 11] . Several structures were proposed for this 223 amino-acids protein and the most accepted model represents the 1 receptor made of three hydrophobic regions two of which are trans-membrane spanning segments. The NH2 and the COOH termini of the 1 protein are on the same side of the cell compartment where a possible endogenous ligand, not yet identified, regulates its function [12] . Progesterone, sphingolipid-derived amines (D-erythrosphingosine) and more recently N,N-dimethyltryptamines have been proposed as 1 endogenous ligands [13] [14] [15] . Because of the important therapeutic potentials (e.g. treatment of anxiety, depression, schizophrenia, etc) linked to1 receptor targeting, interest in 1 receptor research is on the increase [16] . Recent evidence has shown that1 receptor can naturally form dimers and/or oligomer and that heteromers between 1 and D2 receptor play an important role in cocaine addiction [17, 18] . These dimers/oligomers may lead to different functional forms of the 1 receptor (such as agonist or antagonist activity). All these lines of evidence make novel pharmacological tools appealing for the study of the still controversial1 receptor physiology.
With this aim, we produced three 1 receptor fluorescent tracers starting from previously well characterized 1 receptor ligands. We adopted the same strategy that was shown to be successful for 2 fluorescent ligands: the appropriate 1 pharmacophore was linked through a spacer to a green emitting fluorescent tag [19] [20] [21] . In particular, as 1 pharmacophores we selected 4-methyl-1-[4-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)butyl]piperidine PB190 and 4-methyl-1-[4-(6-methoxy-naphthalen-1-yl)butyl]piperidine PB212 (Figure 1 ) which were shown to be respectively a 1 selective agonist and a 1 selective antagonist by both in vitro and in vivo assays [22] [23] [24] [25] [26] . We also selected 4-cyclohexyl-1-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1yl)propionyl]piperazine (Figure 1, 1) which showed excellent 1 affinity and 1 vs 2 selectivity [27] . The methoxy group present in these 1 ligands was replaced by a hexamethylenoxy chain carrying in the  position a 4-N,N-dimethylphthalimide moiety. These choices were made on the basis of data obtained from 2 receptor fluorescent ligands: the position on the naphthalene or tetralin ring and the nature of the linker showed to be well tolerated with 4-N,Ndimethylphthalimide conferring optimal fluorescent properties that allowed successful experiments in living cells by flow cytometry and confocal microscopy.
Results and Discussion

Chemistry
The synthetic pathway for final compounds 5, 6 and 9, is depicted in Scheme 1. The already known piperidines PB190 and PB212 [22] and the piperazine 1 [27] were demethylated by reaction with BBr3 to provide the corresponding phenolic intermediates 2, 3 and 8, although phenol 3 was previously obtained through another synthetic pathway [28] . Alkylation of the phenolic intermediates 2, 3 and 8 with the already known mesyl derivative 4 [20] provided final fluorescent compounds 5, 6 and 9. Final comompounds 6 and 9 were converted into the corresponding hydrochloride salts with gaseous HCl, whereas 5 was converted into the corresponding oxalate salt.
 Receptors Radioligand binding
Results from binding assays are expressed as inhibition constants (Ki values) in Table 1 . As in the σ2 receptors fluorescent ligands, the introduction of the fluorescent tag connected through the hexamethylenoxy linker at the 2-or 5-position of the naphthalene and tetralin ring respectively, produced a decrease in the σ1 receptor affinity with respect to the corresponding lead compounds.
Only compound 5 presented affinity values at both  receptors (Ki = 3.61 nM at the 1, and Ki = 48.3 nM at the 2) comparable to those of lead compound PB190 (Ki = 1.01 nM at the 1, and Ki = 48.7 nM at the 2). Final compounds 6 and 9 presented a 100-fold drop in the 1 affinity (Ki = 5.20 nM and Ki = 13.1 nM, respectively) in comparison to the lead compounds PB212 and 1, respectively (Ki = 0.03 nM and Ki = 0.11 nM, respectively). By contrast, the affinity at the 2 receptors only slightly decreased for 6 (2.5-fold) in comparison to its lead compound PB212, whereas 2 receptor affinity of 9 was 5-fold higher than 2 receptor affinity displayed by 1. Despite the decrease in the 1 affinity compared to the lead compounds, the three fluorescent ligands still demonstrated strong nanomolar σ1 binding, and compounds 5 and 6 also kept a certain 1 versus 2 receptor selectivity (10-fold), which was lower (3-fold) in 9. Taking these data together, the strategy adopted to obtain 2 receptor fluorescent ligands showed to be successful also for 1 receptor fluorescent ligands.
Photolabeling and Cell Viability Assay.
To demonstrate the universality of specific binding of the novel tracers to 1 receptors we performed a photolabeling assay, selecting compounds 6 and 9 bearing structurally different basic moieties and using rat adrenal gland phaeochromocytoma PC12 cell membranes as a convenient source of 1 receptors. As shown in Figure 2 .A, both 6 and 9 effectively protected against photolabeling of 1 receptor by [ 125 I]-Iodoazidophenpropimorph.
Further, as shown in Figure 2 . B, the cytoprotective properties of compound 9 were assessed in a MTT cell viability assay upon toxicity mediated by paraquat. It is clear that compound 9 protects against such toxicity and therefore may be useful for oxidative stress treatments. Table 1 . The three compounds displayed very similar maximum excitation wavelength (λex = 390 nm) and maximum emission wavelength (λem ~ 520 nm), with an important difference between λex and λem (i.e., Stokes shift) in accordance to the spectra recorded for the 2 ligands with the same fluorescent tag [20, 21] . [4, 20] whereas 1 receptors' expression is very low (Bmax = 0.17 pmol/mg protein) [4, 29] ; the latter is obtained by stable transfection of MCF7 cells with 1 c-DNA to obtain a good expression of 1 receptors (Bmax = 3.45 pmol/mg protein) [21, 29] . All of the experiments were performed by incubation of the two cell lines for 45 and 75 min with either compound 5 or 6 at 100 nM, as the fluorescence signal increased in a dose-dependent manner, reaching a plateau at 100 nM. right panels). The fluorescence intensity results obtained by either 5 or 6 in MCF71 cells by dosedependent displacement of the 1 receptor ligands studied, served to generate binding curves for PB190, PB212 and (+)-pentazocine allowing the measurement of the IC50 values of these compounds for the human 1 receptors in MCF7 cells ( Table 2) . Differences between radioligand binding assays performed on animal tissues and human cells homogenates have already been reported for  receptors, with slightly lower binding affinities from the latter experiment [31] . The IC50 values obtained by flow cytometry on MCF7 cells were in accordance with such trend, demonstrating the utility of 1 receptors fluorescent ligand as tools to detect their presence in living cells and to conveniently perform 1 binding assays of novel ligands in spite of the radioligand binding assays.
Fluorescent Ligands Studies.
Fluorescent Properties. The fluorescent properties are listed in
Conclusions
Three 1 fluorescent tracers were synthesized by functionalization of three well characterized 1 ligands with a fluorescent tag. A good compromise between binding affinity at the 1 subtype and fluorescent properties was obtained, with all the compounds displaying low nanomolar 1 receptor affinity. Their  receptor specificity was demonstrated by protection with -specific compounds in different cell lines through different techniques: photolabeling (compounds 6 and 9), confocal microscopy (compound 9) and flow cytometry (compounds 5 and 6). We also demonstrated that through the use of these fluorescent tracers in flow cytometry, 1 binding assays of novel ligands can be conveniently performed in spite of the more classical radioligand binding assays that involves the use of radioligands such as [ 3 H]-(+)-pentazocine. To the best of our knowledge, these compounds are the first 1 fluorescent ligands to be produced and successfully employed, and they emerge as useful tools to empower 1 receptors studies. 
Experimental section
General procedure for the synthesis of phenolic intermediates (2, 3, 8)
A solution of one among the methoxy derivatives PB190, PB212 and 1 (1.0 mmol) in anhydrous CH2Cl2 (10 mL) and under Argon was cooled to -78 °C and then added in a dropwise manner with 
General procedure for the synthesis of final fluorescent compounds (5, 6 and 9).
A solution in DMF (10 mL) of one among the phenol intermediates 2 or 3 or 8 (1.0 mmol) was added with the mesyl derivative 4 (1.0 mmol, 0.37 g) and K2CO3 (1.2 mmol, 0.16 g) to provide a mixture which was stirred at 150 °C overnight. After concentration under reduced pressure the crude residue which was taken up with water was extracted with CH2Cl2 (3 × 10 mL) and the organic phases collected were dried (Na2SO4) and evaporated under reduced pressure to provide a crude oil which was purified by column chromatography (CH2Cl2/MeOH, 95:5) to afford the title compounds. 
Competition Binding Assays.
All the procedures for the binding assays were previously described. 1 And 2 receptor binding were carried out according to Berardi et al. [27] . 
ARPE19 Cell labeling and imaging. Drug treatment and imaging of ARPE cells was done in
HBSS. For control, some wells were pretreated with 100 M PB190 for 40 min. Cells were further treated with compound 9 0.5 M for 40 min, then rinsed twice in HBSS and imaged under A1 confocal microscope with excitation wavelength of 408 nM and emission detection of 525 nM.
MTT cell viability assay.
ARPE 19 cells were seeded to 96 well plates to a density of 30000 cells/well and grown in complete growth medium to reach 100% confluency. Then 1 mM toxin Paraquat was applied with or without various concentrations of compound 9 and cells were incubated tor 24 h in complete growth media.
Then wells were quickly aspirated and Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma-Aldrich M2128) was applied under the dim light at concentration 0.5 mg/ml in phenol red free DMEM (100 l/well) supplemented with fetal bovine serum 0.5%. After 3 hours of incubation 100 l of 10% [33] (approximately 1 nM) was added for 30 min, and the membrane preparations were further incubated in the dark at room temperature. After incubation, the samples were illuminated with an AH-6 mercury lamp for 7.5 s, and Laemmli buffer was added to each sample. Samples were separated by SDS PAGE, the gel was stained and dried, and exposed to a phosphor screen (Molecular Dynamics) for 24 h. The cassette was scanned on a Storm
Phosphoimager (Molecular Dynamics) to produce the resulting autoradiogram. Co.) for 10 min at 37°C, centrifuged at 13,000 × g for 5 min and re-suspended in 500 µL of PBS. The fluorescence was recorded using a Bio-Guava® easyCyte™ 5 Flow Cytometry System (Millipore, Billerica, MA), with a 530 nm band pass filter. For each analysis, 50,000 events were collected and analysed with the InCyte software (Millipore).
Fluorescence Spectroscopy.
Emission and excitation spectra of compounds 5, 6 and 9, were determined in CHCl3 and in PBS buffer solution as previously reported. Fluorescence quantum yields were calculated with respect to quinine sulfate as previously reported [19] .
Abbreviations: DTG, di-2-tolylguanidine; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate buffered saline; SDS, Sodium Dodecyl Sulfate. Ki nM ± SEM (nM) [a] compound 1 2 ex nm [b] em nm [b] QY EtOH [c] QY CHCl3 [c] PB190 [d] 1.01 ± 0.41 48. compound 5 [b] 6 [b] PB190 [ 
